These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2317829)

  • 1. Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity.
    Friedman HS; Colvin OM; Aisaka K; Popp J; Bossen EH; Reimer KA; Powell JB; Hilton J; Gross SS; Levi R
    Cancer Res; 1990 Apr; 50(8):2455-62. PubMed ID: 2317829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer.
    Berger SJ; Gosky D; Zborowska E; Willson JK; Berger NA
    Cancer Res; 1994 Aug; 54(15):4077-83. PubMed ID: 8033140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
    Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS
    Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buthionine sulfoximine reduces the protective capacity of myocytes to withstand peroxide-derived free radical attack.
    Le CT; Hollaar L; van der Valk EJ; van der Laarse A
    J Mol Cell Cardiol; 1993 May; 25(5):519-28. PubMed ID: 8104252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K; Shrieve DC
    J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
    Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK
    Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutathione depletion as a determinant of sensitivity of human leukemia cells to cyclophosphamide.
    Crook TR; Souhami RL; Whyman GD; McLean AE
    Cancer Res; 1986 Oct; 46(10):5035-8. PubMed ID: 3463410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the embryotoxicity of acrolein, but not phosphoramide mustard, by glutathione depletion in rat embryos in vitro.
    Slott VL; Hales BF
    Biochem Pharmacol; 1987 Jun; 36(12):2019-25. PubMed ID: 3593406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of buthionine sulfoximine on the nephrotoxicity of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea (MeCCNU).
    Kramer RA; Schuller HM; Smith AC; Boyd MR
    J Pharmacol Exp Ther; 1985 Aug; 234(2):498-506. PubMed ID: 4020683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery.
    Bertsche U; Schorn H
    Radiat Res; 1986 Mar; 105(3):351-69. PubMed ID: 3754339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral glutamine protects against cyclophosphamide-induced cardiotoxicity in experimental rats through increase of cardiac glutathione.
    Todorova V; Vanderpool D; Blossom S; Nwokedi E; Hennings L; Mrak R; Klimberg VS
    Nutrition; 2009; 25(7-8):812-7. PubMed ID: 19251394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in mice.
    Soble MJ; Dorr RT
    Res Commun Chem Pathol Pharmacol; 1987 Feb; 55(2):161-80. PubMed ID: 3823607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of cyclophosphamide-induced urotoxicity by buthionine sulfoximine and disulfiram in mice.
    Ishikawa M; Takayanagi Y; Sasaki K
    Res Commun Chem Pathol Pharmacol; 1989 Aug; 65(2):265-8. PubMed ID: 2587846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
    Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS
    Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aqueous extract of Trigonella foenum-graecum L. ameliorates additive urotoxicity of buthionine sulfoximine and cyclophosphamide in mice.
    Bhatia K; Kaur M; Atif F; Ali M; Rehman H; Rahman S; Raisuddin S
    Food Chem Toxicol; 2006 Oct; 44(10):1744-50. PubMed ID: 16828947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of selenium deficiency and glutathione-modulating agents on diquat toxicity and lipid peroxidation in rats.
    Awad JA; Burk RF; Roberts LJ
    J Pharmacol Exp Ther; 1994 Sep; 270(3):858-64. PubMed ID: 7932197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of cisplatin toxicity by buthionine sulfoximine, a glutathione-depleting agent, in mice.
    Ishikawa M; Takayanagi Y; Sasaki K
    Res Commun Chem Pathol Pharmacol; 1990 Jan; 67(1):131-41. PubMed ID: 2326543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of phorone and/or buthionine sulfoximine on teratogenicity of 5-fluorouracil in mice.
    Naya M; Mataki Y; Takahira H; Deguchi T; Yasuda M
    Teratology; 1990 Mar; 41(3):275-80. PubMed ID: 2326751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of L-buthionine-[S,R]-sulfoximine on the pancreas in mice. A model of weakening glutathione-based defense mechanisms.
    Lüthen RE; Neuschwander-Tetri BA; Niederau C; Ferrell LD; Grendell JH
    Int J Pancreatol; 1994 Aug; 16(1):31-6. PubMed ID: 7528760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.